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Abstract
Glioblastoma multiforme (GBM) is the most common and malignant form of primary brain 
tumors. It is highly invasive and current treatment options have not improved the survival rate over 
the past twenty years. Novel approaches and technologies from systems biology have the potential 
to identify biomarkers that could serve as new therapeutic targets for GBM. This study employed 
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lipid profiling technology to investigate lipid biomarkers in ectopic and orthotopic human GBM 
xenograft models. Primary patient cell lines, GBM10 and GBM43, were injected into the flank 
and the right cerebral hemisphere of NOD/SCID mice. Tumors were harvested from the brain and 
flank and proteins, metabolites, and lipids extracted from each sample. Reverse phase based high 
performance liquid chromatography coupled with Fourier transform ion cyclotron resonance mass 
spectrometry (LC-FTMS) was used to analyze the lipid profiles of tumor samples. Statistical and 
clustering analyses were performed to detect differences. Over 500 lipids were identified in each 
tumor model and lipids with the greatest fold effect in the comparison of ectopic versus orthotopic 
tumor models fell predominantly into four main classes of lipids: glycosphingolipids, 
glycerophoshpoethanolamines, triradylglycerols, and glycerophosphoserines. Lipidomic analysis 
revealed differences in glycosphingolipid and triglyceride profiles when the same tumor was 
propagated in the flank versus the brain. These results underscore the importance of the 
surrounding physiological environment on tumor development and are consistent with the 
hypothesis that specific classes of lipids are critical for GBM tumor growth in different anatomical 
sites.
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INTRODUCTION
Glioblastoma Multiforme (GBM) is the most common and aggressive form of primary brain 
tumor [1], and is one of the most invasive and malignant cancers described. Usually, by the 
time of diagnosis a primitive subpopulation of GBM tumor cells has already migrated from 
the primary tumor site and infiltrated the distant brain parenchyma, making it impossible to 
cure [2]. GBM can occur at all ages but is found more frequently in older adults [3]. 
Although advanced diagnostic modalities, surgical techniques, and adjuvant treatment 
strategies have been developed over the last 30 years, the prognosis of GBM has not 
significantly changed over several decades [4]. GBM has a median survival period of 
approximately 12 to 15 months from diagnosis with a two-year survival rate of only 5 – 15% 
[5]. Due to the extremely aggressive nature of this cancer, current treatment options focus 
primarily on extending the lifespan of the patient [6].
Systems biology approaches using genomics and proteomics have been employed to 
investigate the characteristics of cancer progression and discover potential biomarkers and 
new therapeutic targets. Progression of gliomas is due to genetic and epigenetic alterations, 
including the loss of tumor suppressor gene function and activation of oncogenic pathways 
[2]. More than 500 human GBM tumors have been sequenced and characterized [7] and 
whole proteome analyses of gliomas have been performed using various human samples [8]. 
Lipidomics offers another important avenue to further understand the molecular mechanisms 
controlling GBM progression and may yield new therapeutic targets for GBM, 
complementary to the existing knowledge base generated by efforts in genomics and 
proteomics.
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Lipidomics was introduced in 2003 by Han and Gross [9] and is a relatively new field [8]. 
Due to the membrane organizing properties of lipids, lipids play many important roles in a 
cell, tissue, and organ physiology. The main biological functions of lipids are quite diverse 
and critical for cell growth. Lipids function as structural components of cellular membranes 
and in energy storage. Changes in cell membrane composition can affect cell signaling, 
endocrine actions, membrane trafficking, and regulation of membrane-associated proteins 
[10]. Involvement of lipids may be more critical in the brain function since the human brain 
has the highest lipid content of all organs. The dry weight of the human brain contains 50% 
to 60% lipids [11]. Recent studies have shown that lipid metabolism plays an important role 
in cancer initiation and progression and is regulated by oncogenic signaling pathways [12]. 
The role of lipids in cancer, however, is still poorly understood due to biological and 
technical difficulties [10, 13]. Most analyses of lipids in cancer have been indirect, using the 
examination of enzymes in lipid biosynthesis pathways to predict the potential composition 
and function of lipids within the cell. In addition, information gathered from genomics and 
proteomics analyses has not been well integrated with lipidomics analyses.
We hypothesize that the lipid composition of GBM tumors is critical to tumor maintenance 
and progression. As a first step in addressing this hypothesis, we utilized two types of 
primary human GBM tumor cell lines (GBM10 and GBM43) in ectopic and orthotopic 
xenograft mouse models and examined the lipid profile in these models. Our overall 
objective was to determine if different anatomic sites (flank versus intracranial) resulted in 
distinct lipid profiles. This study also represents a multidisciplinary collaborative effort to 
improve the efficiency of computational pipelines. Development of appropriate 
infrastructure and pipelines that provide high quality and clinically relevant tissue are 
imperative to the analytics, visualization, identification, and interpretation of the “omics” 
data; such studies regularly serve as case studies for pipeline advancement efforts and 
identification of therapeutic biomarkers [14].
EXPERIMENTAL PROCEDURES
Cell Lines and Cell Culture
Parental primary human GBM xenograft lines GBM10 and GBM43 were surgically 
removed and provided by Dr. Jann Sarkaria (Mayo Clinic, Rochester, Minnesota). Both cell 
lines are resistant to temozolomide and molecular properties have been described and 
validated in low passage lines (GBM10: wildtype EGFR, wild-type p53, CDKN2A/
p16deleted, wild-type PTEN, and MGMT positive; GBM43: mutant p53, CDKN2A/
p16deleted, wild-type PTEN, and MGMT positive [15]). GBM10 and GBM43 cells were 
expanded as flank tumors, harvested and maintained in 2.5% FBS for 4 days on matrigel-
coated plates to remove murine fibroblasts. Cells were expanded in DMEM/F12 (Gibco 
#11965 Dulbecco’s Modified Eagle Medium; 4.5g/L D-glucose and L-Glutamine) with 10% 
FBS (Atlanta Biologicals Advantage FBS #S11050) for less than 2 weeks and used for set 
up of intracranial models. Cells were checked for mycoplasma prior to injection into mice 
and were negative. In each mouse, 3×105 cells were surgically implanted into right cerebral 
hemisphere and 3 × 106 cells subcutaneously injected into the right flank. An overview of 
biological sample preparation workflow is shown in (Fig. 1).
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Human GBM Xenograft Models
NOD.CB17-Prkdcscid/J (NOD/Scid) mice were obtained from the onsite breeding colony in 
the In Vivo Therapeutics Core at the Indiana University School of Medicine. Five mice were 
utilized per GBM cell line. GBM10 and GBM43 cells were implanted in the right flank in 
matrigel at 3 × 106 cells per mouse. Flank and intracranial tumors were implanted in the 
same mice. For intracranial implantation, a digitalized stereotaxic delivery system was 
utilized (David Kopf Instruments, Model 5000 microinjection unit, Tujunga, CA) as 
described previously [16, 17]. For stereotaxic delivery of tumor cells, mice were placed 
under general anesthesia (ip injection of 16 mg/kg xylazine and 120 mg/kg ketamine) and 
positioned in the stereotaxic device. A digitalized drill assembly was used to bore a hole 0.3 
mm in depth and 0.8 mm diameter in the cranium at a position 0.5 mm anterior and 1.2 mm 
lateral to the bregma anatomical landmark. Tumor cells (3 × 105) in 10 μl of PBS) were 
introduced slowly using a 10 μl Hamilton syringe at a depth of 3.5 mm at a rate of 2 μl/min. 
Once injection was complete, the needle was kept in place for at least 5 minutes and then 
slowly removed and the hole sealed with bone wax. The incision was closed with 3M 
vetbond Tissue Adhesive (3M Animal Care Products). In previous validation studies, 
bioluminescence imaging of xenograft tumors that express a luciferase-enhanced green 
fluorescent protein (EGFP) fusion protein was performed in order to detect the tumors in the 
brain and flank sites (Fig. 1B). Survival analysis using pre-death endpoint criteria was also 
previously performed and the median survival is typically 35–55 days post-implantation of 
tumor cells for GBM10 and 30–40 days for GBM43 in NOD/Scid mice (unpublished 
observations, Wang and Pollok). Mice with flank tumors were euthanized once tumors 
reached ~250 mm3. Tumors were excised and flash frozen and stored at −80°C. For mice 
with intracranial tumors, the mice were observed twice daily starting at 2 weeks and prior to 
reaching the pre-death endpoint were euthanized. Tumor tissue was carefully excised from 
the right cerebrum and control tissue from the left cerebrum; tissues were immediately flash 
frozen, and stored at −80°C until analysis.
Lipid Extraction
Sample preparation of the mouse tumors prior to mass spectrometry was performed using a 
novel biomolecule extraction method to simultaneously harvest the proteins, metabolites, 
and lipids in one simple and fast procedure visualized in (Fig. 2). Proteins and hydrophilic 
metabolites of the mice tissues were collected and stored for the future analyses. Ten to 100 
mg of in vivo mouse GBM tumor tissues were placed in a low retention 2.0 ml 
microcentrifuge tubes and placed on ice. These tumor samples were mixed with 200 μl of 
75% MetOH in 0.15M NaCl. Approximately 50 μl of grinding balls (ZrO; diameter ~0.5 
mm) were added to each tube in order to homogenize the tumor tissues using Next Advance 
Bullet Blender for two minutes. This step was repeated until the tissues were completely 
homogenized. After the tissue homogenization, 20 μl of suspension from each tube was 
transferred into the new 1.5 ml microcentrifuge tubes and mixed with 180 μl of 0.15M NaCl 
and 1 ml of chloroform/methanol (2:1) with 0.01% BHT by vortex for two minutes, then 
incubated at room temperature for 30 minutes. After the incubation, the tubes were 
centrifuged for five minutes at 7,800xg and 250 μl of the lower chloroform phase of the 
mixtures was transferred into the new tubes and labeled as ‘lipid’ fraction. These lipid 
fractions were stored in −80°C until LC-MS analysis.
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LC-MS Analysis
All analyses were carried out using an Agilent 1200 Series HPLC, ACE 5 C8-300 column 
(2.1 × 100 mm) and linear gradient elution at a flow rate of 0.1 mL/min. Injection volume 
was 4 μL. The mobile phases were composed of (A) 0.1% formic acid and 10 mM 
ammonium acetate in H2O, and (B) 0.1% formic acid, 10 mM ammonium acetate in ACN/
Isopropanol (50/50; v/v). Separation of lipids was achieved at the following gradient: T=0 
min: 30% B; T=1 min: 30% B; T=25 min: 100% B; T=45 min: 100% B; T=47 min: 30% B; 
and T=60 min: 30% B (column re-equilibration).
HPLC system was directly coupled to a Bruker solariX 70 Hybrid FTMS instrument 
equipped with electrospray ionization source (ESI). The system was controlled by HyStar v.
3.4.8.0 software (Bruker Daltonics). MS data was collected with resolving power of 78,000 
(at m/z 400) in positive or negative mode under following conditions: a capillary voltage of 
(+/−) 4,500 V and an end plate offset of −500 V. The dry temperature was set at 180 °C. Dry 
gas flow was maintained 4 L/min. Acquisition range was 244 – 1,800 m/z with 0.2 s ion 
accumulation time.
Data Processing & Statistical Analysis
LC-MS data was converted into mzXML format using CompassXport v. 3.0.6. (Bruker 
Daltonics) and processed by the mzMine v.2.10 data analysis software. Data processing 
involved mass detection, chromatographic peak detection and deconvolution, gap filling, 
isotopic peaks grouping, normalization and peak alignment. To determine the most 
significant changes, a series of homoscedastic t-tests comparing GBM10 and GBM43 brain, 
flank, and control tumors in all possible permutations was performed. The corresponding 
lipids were tentatively identified using LIPID MAPS, a web-based lipid database, that uses a 
textual and ontological search to identify sub class, class, and common structure of a lipid 
within a variable m/z tolerance of 0.02 m/z, representing the closest catalogued lipid. 
Additional structure was not elucidated. (LIPID MAPS Lipidomics Gateways, 2014).
Ethics Approval
All studies were reviewed and approved by the Indiana University Animal Care and Use 
Committee (IACUC #10103) or the Purdue University Institutional Biosafety Committee 
(IBC 10-003).
RESULTS
Mass Spectrometry Data Overview
Flank and brain tumor samples derived from two primary human GBM tumor cell lines, 
GBM10 and GBM43, were collected and analyzed. Lipid profiles of intracranial tumors 
versus control brain tissue and intracranial tumors versus flank tumors were determined. 
Among all 26 samples, which were actually extracted and analyzed, 11,218 unique positive-
ion mode peaks were quantified by mzMine2, representing an m/z ratio range of 244 to 
1,800. To filter out insignificant peaks, a truncated data set was created by removing any 
peak detected in fewer than five samples, as there were five replicate samples in each model 
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grouping. This yielded 4,422 positive-ion mode peaks. A similar process for data ran in the 
negative-ion mode yielded 725 unique peaks.
Positive and negative ion mode of electrospray ionization (ESI) mass spectra was used to 
distinguish different charge state distribution of the ions in macromolecules. Generally, the 
positive ion mode detects the ion peaks in different protonation states [18]. As described in 
the material and methods, GBM10 and GBM43 cells were implanted in the flank and right 
cerebral hemisphere in each mouse on study. Sufficient sample size of 10 mg or greater was 
required for analysis and was obtained in all GBM10 and GBM43 intracranial tumors and 
for GBM10 flank tumors (n=5 per group). For GBM43 implanted mice, intracranial tumors 
progressed faster than the flank GBM43 tumors. Therefore it was necessary to euthanize 
GBM43-implanted mice at a time point when only four out of five mice had measurable 
flank tumors; this was necessary in order to capture high quality intracranial GBM43 tumor 
tissue for extraction and subsequent lipid analyses. At this time point, three out of four 
GBM43 flank tumors were too small (1–2 mg) for extraction. Lipid profiling was completed 
on the GBM43 flank tumor of sufficient size. In order to compare the tumor lipid profiles 
against the normal brain lipid profiles, t-test was performed between the tumor and normal 
brain profiles of GBM10 (both flank and intracranial tumors) and GBM43 (intracranial 
tumors only). Of the positive-ion mode data, 368 lipids were identified to be significantly 
different in lipid levels between GBM10 brain tumor tissue and the control brain tissue, 305 
lipids between GBM43 brain tumor tissue and the control brain tissue, and 1926 lipids 
between GBM10 flank tumor tissue and control brain tissue. Interestingly, GBM10 flank 
tumor profiles showed a higher number of lipid differences compared to the brain tumor 
profiles. Of the negative-ion mode data, 149 lipids were expressed at significantly different 
levels between GBM10 brain tumor tissue and the control brain tissue, 233 lipids between 
GBM43 brain tumor tissue and the control brain tissue, and 157 lipids between GBM10 
flank tumor tissue and the control brain tissue. All these lipids had a fold effect change of 
one or greater and p-value less than 0.05 from the t-test. A summary of the number of 
significant lipids from the tumors propagated at different anatomical sites (flank versus 
intracranial sites) and the ratio of significantly decreased and increased lipids compared to 
control brain tissue is shown in Table 1. More than 500 lipid species were detected at 
significantly different levels in tissues derived from the flank versus the brain, and more than 
90% of these lipids were decreased in both GBM10 and GBM43 brain and flank tumors 
when compared to control brain tissue. The data supports that GBM tumor tissue contains 
dramatically lower levels of lipids and a different lipid composition than normal brain tissue.
Comparison of Lipid Profiles in Orthotopic Versus Ectopic Xenograft Tumors
We next investigated differences in overall lipid composition between tumor tissues derived 
from the same primary human GBM cell lines but located in distinct anatomical sites. A t-
test was used to compare the lipid profiles of the all brain tumors and all flank tumors in the 
same manner as the comparison between the tumor and the control profiles. 1960 lipids were 
differentially expressed on the positive-ion mode profile of the flank tumor compared to the 
brain tumor profiles and 206 lipids were differentially expressed on the negative-ion mode 
profile (Table 2). All these lipids also had the fold effect change of one or greater and p-
value less than 0.05 based on the t-test. As shown in Table 2, the majority of these lipids 
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were decreased in flank tumor tissues compared to brain tumor tissues. Differentially 
expressed lipid types between brain and flank tumors support the pattern in (Fig. 3), which 
expresses m/z range and different fold effect change among the brain tumors and the flank 
tumors. In general, lipidomic profiles of the flank tumors of GBM expressed a greater fold 
change when compared to the brain tumor profiles. The range of the lipid fold change of the 
flank tumors was between approximately 20 to 30 and −35 to −20. In contrast, brain tumors 
of both GBM10 and GBM43 showed a fold effect change range between −5 and 5.
Significantly Different Lipid Levels and Composition in GBM
Most of the 500 significant lipids identified were from the lipid classes of 
glycosphingolipids, glycerophosphoethanolamines, triradylglycerols, 
glycerophosphocholines, and glycerophosphoserines. The thirty lipids with the highest 
differences in fold effect from the comparison of GBM43 brain tumor versus the control, 
GBM10 brain tumor versus the control, and flank tumor versus the control were selected 
from the larger group for closer examination. These lipids fell mostly into four main lipid 
classes: glycosphingolipids, glycerophosphoethanolamines, triradylglycerols, and 
glycerophosphoserines. There were three compounds among top 30 significant lipids 
identified from each tumor type that were identified in both positive and negative mode. 
These identified lipids were Glycerophosphoglycerols (mass= 788.59, PG(38:2)/PG(38:1)), 
Glycerophosphocholines/Glycerophosphoethanolamines (mass=753.55, PC(35:5)/PC(34:4), 
PE(38:4)/PE(37:4)), and Glycerophosphocholines (mass=873.71, PC(42:0)). Fig. (4) is a 
visual comparison of the differences in lipid concentration among the tissue types.
The positive and negative ion profiles revealed differences in the level and composition of 
lipid classes among brain and flank tumors. The positive ion profiles of 
glycerophosphoserines showed decreased levels of lipids in GBM43 brain tumor tissue and 
flank tumor tissue. There were only a few increased levels of lipids from GBM10 and GBM 
43 tumor tissue (Fig. 4A). The negative ion profile of glycerophosphoserine did not show 
any increased levels of lipids and the majority of the decreased lipids were expressed in 
flank tumor tissue (Fig. 4B). Glycerophosphocholines were identified as the most frequently 
identified lipids in the negative ion profiles among different tissue sources and also showed a 
decreased pattern of lipid levels (Fig. 4D). Some of the flank tumor lipids from the positive 
ion profiles of glycerophosphocholine were increased in comparison to the control, while the 
negative ion profiles showed a similar distribution of lipids for all three tumor tissue types: 
GBM10 brain tumors, GBM43 brain tumors, and all flank tumors. Glycerophosphocholines 
in flank tumor tissue, however, had higher fold change than brain tumor tissue (Fig. 4C). The 
profiles of glycerophosphoethanolamines had a similar trend of decreased level of lipids. 
The level of glycerophosphoethanolamines in GBM10 brain tumor tissue often increased in 
the positive ion profiles, while GBM43 and flank tumor tissue showed decreased fold 
change (Fig. 4E). The negative ion profiles of glycerophosphoethanolamines were similar to 
glycerophosphocholines (−) with decreased levels of lipids (Fig. 4F). The positive ion 
profiles of triradylglycerol plot showed lipids primarily from flank tumor tissue. Some lipids 
of GBM10, GBM43, and flank tumor were decreased, yet overall, the majority of the levels 
of lipids that were detected from flank tumor tissue were increased (Fig. 4G). Several lipid 
classes and structures were significant in both the positive and negative mode, namely 
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glycerophosphoserines, glycerophosphocholines, and glycerophosphoethanolamines (Fig. 
4).
Hierarchical Clustering of GBM Tumors
For quality assurance purposes, a series of analytical approaches were employed in order to 
identify any definite peculiarities associated with the results. In particular, special attention 
was paid to determine whether the data for the samples demonstrated affinities consistent 
with the grouping of the samples. For this purpose, an analysis using a set of clustering 
algorithms, Divisive ANAlysis (DIANA) and AGglomerative NESting Hierarchical 
Clustering (AGNES), was performed. Clustering is a widely adopted technique that is 
unsupervised and data-dependent in that it explores the relationships between all of the 
variables and not simply the targeted ones [19], and we chose clustering to avoid introducing 
bias into our quality assurance efforts. To generate the clusters of the samples, m/z values 
and peak intensities from MzMine2 data were compared. As a result, the output from 
DIANA and AGNES showed similar patterns of clusters while these two algorithms have 
distinctly different paths to generate the output [20] and have a history of use with similar 
data [14].
As is evident from (Fig. 5), these disparate approaches produced closely related results. All 
the figures generated from DIANA and AGNES showed a propensity for the flank subjects 
to clearly cluster away from the other tissue types while the brain and control groups 
demonstrate a more closely clustered set of results. However, even in the brain and control 
groups, each group tended to segregate in the expected cohorts. Based on the evidence 
rendered from using DIANA and AGNES, it is likely that the results achieve the 
aforementioned affinities, and accordingly the pattern mining efforts help to establish the 
validity of the experimental protocol.
DISCUSSION
GBM Cell Lines and Tumor Size
Two human primary GBM cell lines, GBM10 or GBM43, were used in ectopic and 
orthotopic mouse xenograft models and harvested after adequate tumor growth and 
expansion. In addition to the lipid profile differences described in this study, qualitative 
differences were also observed among the tumors derived from either GBM10 or GBM43. 
Fig. (6) was generated to compare the tumor and normal brain tissue sizes obtained from the 
different tissue types. All tissue types contained sample size of five (n=5) each. The box plot 
of the tumor size shows that the size of GBM43 flank tumors was significantly smaller 
compared to other tumor tissues. The analysis of lipid profiling was done in one out of the 
four GBM43 flank tumors and the results were consistent with observations in the GBM10 
model in that different lipid profiles exist overall in tumors propagated in the flank versus 
the brain. Flank tumor tissues were also more difficult to homogenize during the extraction 
procedure when compared to brain tumors and control samples. Control brain and brain 
tumor tissues were mostly homogenized on the first attempt. However, most of the flank 
tumors from GBM10 and GBM43 were homogenized up to five times in order to adequately 
break down the tissue for subsequent analysis. Observed morphological differences in the 
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tumors may be due to molecular differences between GBM10 and GBM43. Previous studies 
have reported that GBM10 is wildtype for p53 but GBM43 is mutant for p53 [15]. p53 is a 
tumor suppressor protein that has many functions in cancer cells, including lipid metabolism 
[21].
Biological Sample Preparation for Mass Spectrometry
The novel protocol for concurrent protein, metabolite, and lipid extraction from a single 
sample was designed for a sample tissue size between 10mg and 100mg and helps address 
current limitations in sample preparation of proteins, metabolites and lipids, thus resulting in 
multiple benefits. First, simple and minimal procedures can save sample preparation time, 
minimize degradation of metabolites, and lower sample loss during preparation period. 
Secondly, the bio-molecular samples isolated from this protocol include a wide range of 
lipids, metabolites and proteins, which is beneficial for untargeted omics studies. Thirdly, 
due to the simple and fast sample preparation steps, the method is easily reproducible. 
Systems biology approaches use a large number of samples and reproducibility is critical 
[22].
Data Analysis
Quantitative analysis of the detected lipids revealed patterns that indicate noteworthy 
differences between tumor location in the mouse xenograft model of GBM. As previously 
mentioned, cursory analysis using t-tests and manual identification indicated that while the 
general lipid profiles of flank tumors and brain tumors appeared to be in a similar m/z range, 
a comparison of lipid classes showed differences in the content of lipids. Hierarchical 
clustering indicates distinct profiles of lipids in flank tumor tissues distinguished from both 
brain tumor and brain control tissue, while brain tumor and brain control tissue cluster 
together. This evidence may suggest that control brain and brain tumor tissues were more 
closely related to each other than flank tumor tissues. The clustering output may also imply 
that certain ‘background noise’ from surrounding tissue of the tumor (i.e. the variance in 
lipid composition of brain tissue and flank tissue) can account for a small portion of this 
clustering pattern.
Beyond the hierarchical clustering of the data, lipid identification introduces an element of 
uncertainty into the analysis. Because the mass spectrometer returned hundreds of 
significantly differentially regulated lipids, many of which shared nearly identical m/z ratios, 
power of manual analysis is influenced by both (1) the resolution of the LipidMaps database 
and (2) the size of the database (containing just over 37,500 unique lipids). The potential of 
fragmentation and creation of adducts within the ion generator, though roughly accounted 
for by mzMine2, add further complication to the manual identification of lipids. The 
instrument used, a Bruker 7-Tesla FT-MS, utilizing the solariX platform, provides mass 
accuracy on the magnitude of greater than under one part per million, which greatly 
increases the certainty of database returns on lipid identification. Likewise, the soft-
ionization of the electrospray limits fragmentation and is compatible with front-coupled 
RHPLC used to separate lipids prior to analysis in the spectrometer.
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Lipid Studies and Decreased Level of Lipids in GBM
Our data showed that more than 90% of significantly identified lipids from brain and flank 
GBM tumors were decreased compared to the control brain tissue. The majority of studies 
exploring lipid metabolism in cancer have reported increased levels of fatty acid synthesis 
[23]. Lipidomic analysis is difficult due to the specificity and complexity of lipid 
composition and the lack of techniques for analysis [10]. In addition, the regulation and 
complex mechanisms of lipid composition associated with cellular homeostasis are still 
poorly understood [13]. There are also limitations in the use of mass spectrometry for the 
structural identification of lipids. It is extremely difficult to accommodate all lipid classes 
using existing current detection methods due to the number and variety of classes and 
molecular species of lipids [10]. Thus most studies focus on investigating lipids indirectly by 
examining the proteins involved in lipid metabolism instead of directly measuring the 
composition of lipids in cancer cells. Some previous studies have examined the correlation 
between membrane lipid composition and malignancy of brain tumors. Campanella and 
colleagues (1992) measured membrane lipid changes among different grades of human 
gliomas using HPTLC. They concluded that higher levels of malignant glioma have 
significantly lower levels of total plasma membrane lipids in tumor tissues [24]. More 
recently, Eberlin and colleagues (2012) used mass spectrometry to classify types of gliomas 
and showed that the total lipid abundance profile of grade IV astrocytoma was lower than the 
low-grade astrocytomas [25].
Normal cells use mainly glucose and fatty acids to generate energy and fulfill the 
requirements for cell growth. However, cancer cells use an altered metabolism in order to 
sustain rapid growth. This altered metabolism, where cancer cells use higher levels of 
glucose to generate energy by anaerobic glycolysis rather than aerobic glycolysis through 
the tricarboxylic acid (TCA) cycle, is called Warburg effect [26]. As shown in (Fig. 7), the 
decreased levels of lipids observed in the glioblastoma tumor tissue may suggest that GBM 
depends on fatty acids as a fuel source in addition to glucose from anaerobic glycolysis. 
Potentially, an increased level of lipolysis in the GBM cancer cell generates energy for 
cancer cell proliferation and results in an overall decreased level of lipids detected. Other 
studies have shown that fatty acids and internal structures are used as an energy source under 
starvation conditions, such as in a tumor environment [27] and that the lipolytic enzyme, 
monoacylglycerol lipase (MAGL), is highly upregulated in aggressive forms of cancer [23]. 
Inhibition of MAGL subsequently inhibited migration, invasion, and survival characteristics 
of cancer cells in both in vitro and in vivo models [23].
The central nervous system has specialized pathways for lipid synthesis and degradation 
related to its specialized physiology and function [28]. Two scenarios may thus result in a 
decrease in the lipid composition: lipid rich brain tissue replacing less lipid rich tumor cells 
would decrease the amount of lipids overall while tumor cells would also likely exploit 
normal physiological pathways related to lipid metabolism in central nervous tissue. There 
are numerous reports in the literature that fatty acid synthetase (FASN) is highly upregulated 
in a variety of cancers including GBM and may be a good therapeutic target [29, 30]. Future 
studies will employ more robust methods of lipid identification to confirm the findings of 
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this work, as well as explore the mechanism related to the decrease in lipid composition by 
examining the metabolic profile and cellular composition of the tumors.
Lipid Function and Fatty Acid Oxidation
Cellular growth requires energy. High levels of lipids are critical for building membranes 
and are required in rapidly proliferating cancer cells. Cancer cells can use anaerobic 
glycolysis to maintain energy levels in a cancer environment through the Warburg effect 
[31]. Some types of cancer also use alternative energy sources, as shown in aggressive 
cancer cell lines that express higher levels of free fatty acids [32]. Research suggests that 
prostate cancer does not depend on glucose for survival and instead may depend heavily on 
fatty acid oxidation for cancer cell growth [33]. Fatty acid oxidation also has a critical role in 
the proliferation and survival of leukemia [34]. Fatty acid oxidation has also been shown to 
contribute to energy production and resistance to oxidative and nutrient stress in GBM [35].
Recent articles [36, 37] have cautioned about the impact of experimental conditions on the 
reproducibility of systems biology experiments. An important consideration for team-based 
science is establishing a pipeline that ensures reproducible handling and processing of 
samples and data along multiple steps. Through this study, we have established a pipeline for 
the identification of molecular changes in a model system for GBM, including a 
multidisciplinary team of research scientists, clinicians and statisticians with expertise in 
current technologies.
CONCLUSION
Overall, we found that GBM xenograft tumors had significantly lower levels of lipids when 
compared to the normal brain tissue. Our results suggest that GBM may use fatty acid 
oxidation as an additional energy source in a nutrient deprived cancer environment (Fig. 7). 
It is also possible that the lower level of lipids could reflect changes in the cellular 
composition of the tumor over time. Normal brain tissue has extensive cellular insulation 
that includes lipid-rich myelin. As normal neuronal cells become replaced with tumor cells, 
the lipid-rich myelin may decrease and subsequently the overall lipid profile in the tumor 
would decrease. The profile for the flank tumors also decreased, however, and thus it is 
likely that multiple factors contribute to the changes we observed in the lipids.
Models for cancer systems are complex and have limitations that must be balanced with 
experimental needs and objectives. We explored differences in tumors promoted by two 
human primary tumor cell lines when placed in two distinct environments, the flank or the 
brain, within a mouse model system for glioblastoma multiforme. Lipid expression profiles 
and statistical clustering analysis revealed that tumors from the flank were different from 
tumors in the brain, suggesting that the molecular profile of the tumors was dependent upon 
the environment. The ease of homogenization during the biomolecule extraction revealed 
differences in physical characteristics between the brain tumors and flanks tumors. The 
physical differences were supported by molecular profile differences in classes of significant 
lipids between the two xenograft tissues as flank tumors showed higher fold effects overall 
when compared to brain tumors. This has implications for future studies using mouse 
xenograft models to examine the molecular mechanisms that control the progression of 
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GBM and the impact of potential therapeutic interventions. Studies using tumors propagated 
in foreign micro-environments such as the flank while informative in initial stages of 
exploration must be used with caution when testing the efficacy of anti-cancer therapies.
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Fig. 1. 
Overview of lipidomic analysis of GBM workflow. (1 A) Number of brain and flank tumors 
of GBM10 and GBM43. (1 B) In vivo tumor harvest information and mouse xenograft 
model validation via bioluminescence imaging. (1 C) Biomolecule extraction procedure. (1 
D–E) Separation and ionization of lipid method for mass spectrometry. (2 A–B) Data 
processing of mass spectrometry data using MzMine2. (2 C) Statistical analysis (2 D) Lipid 
identification using the database, LIPID MAPS. (2 E) Validation of the data by performing 
hierarchical clustering.
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Fig. 2. 
GBM biological sample preparation for omics study. (A) GBM10 and GBM43 cells were 
expanded as flank tumors and harvested. Human GBM10 and GBM43 tumor cells were 
cultured and expanded in vitro prior to implantation. (B) GBM cells were then implanted 
into the flank (3×105 cells/flank) and the right cerebrum (3×106 cells/brain) of each mouse 
and tumors were allowed to develop for 21 to 24 days. (C) Tumor samples from intracranial 
and flank sites were harvested by excision. The tumors were flash frozen immediately and 
stored in −80°C. (D) Proteins, metabolites, and lipids of GBM were extracted. The 3 
fractions of the biomolecules (polar metabolite, protein, and lipid) are indicated.
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Fig. 3. 
m/z and fold effect comparison of each tissue type. The m/z and fold effect range of 
differentially expressed lipids between brain and flank tumors are indicated. In general, 
lipidomic profiles of the flank tumors of GBM expressed a greater fold change (between 
−35and −20) when compared to the brain tumor profiles. m/z value of the identified lipids 
were mostly concentrated in the range of 750 and 900.
Ha et al. Page 17
Anal Chem. Author manuscript; available in PMC 2016 April 29.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Fig. 4. 
Decreased trend of thirty significantly expressed lipids and lipid classes. Thirty most 
significantly identified lipids from each tissue type (all flank, GBM10 brain, and GBM43 
brain tumors) were plotted and grouped in four lipid species. These lipids include 
glycerophosphoserines, glycerophosphocholines, glycerophosphoethanolamines, and 
triradylglycerols. * symbol on the lipid structure represents the lipids that are identified as 
more than one lipid classes.
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Fig. 5. 
Hierarchical clustering output of xenograft tissues. Two different hierarchical clustering 
methods (DIANA and AGNES) were utilized to validate the data analysis method. Clusters 
were created by m/z values and peak intensity from the data generated by MzMine2. Top 
two graphs were generated from the positive ion mode data and bottom two graphs were 
generated from the negative ion mode data.
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Fig. 6. 
Tumor size comparison between different GBM tumors and control brain tissue. The box 
plot represents the tumor size of different tissue types. The mass of GBM10 brain tumors 
(n=5), GBM43 brain tumors (n=5), and GBM10 (n=5) tumors were similar. However, the 
size of GBM43 flank tumors (n=5) from the xenograft model was significantly smaller 
compared to other tumor tissues. One of GBM43 flank tumor did not grow, which counted 
as 0mg. Four tumors were harvested for the lipid extraction. However, three among these 
four tumors were too small for the extraction.
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Fig. 7. 
Normal cells primarily use glucose to generate energy and fulfill the requirements for cell 
growth. Cancer cells alter glucose metabolism and bypass the TCA cycle through the 
“Warburg effect,” in order to sustain rapid cell growth. Decreased amounts of lipids, which 
may occur through lipolysis in cellular organelles such as ER and Golgi, may suggest that 
glioblastoma cells use fatty acids as an alternative fuel source.
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Table 1
Differentially expressed significant lipids in different types of GBM tissues and control brain tissues.
GBM10 Brain GBM43 Brain GBM10 Flank
Positive ion mode Over-expressed 26 21 360
Under-expressed 342 (92.9%) 284 (93.1%) 1566 (81.3%)
Negative ion mode Over-expressed 2 0 4
Under-expressed 147 (98.7%) 233 (100%) 153 (97.5%)
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Table 2
Differentially expressed significant lipids of flank tumors compared to brain tumors.
Number of lipids
Positive ion mode Negative ion mode
Over-expressed 267 7
Under-expressed 1693 199
Anal Chem. Author manuscript; available in PMC 2016 April 29.
